LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Inicio・Lista de Acciones・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Cerrado

SectorSanidad

85.38 0.99

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

83.01

Máximo

85.43

Métricas clave
By Trading Economics
Ingresos	-252M -129M
Ventas	-295M 157M
Margen de beneficios	-82.062
Empleados	1,069
EBITDA	-254M -103M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+14.92% upside

Dividendos
By Dow Jones
Próximas Ganancias	25 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.1B 14B
Apertura anterior	84.39
Cierre anterior	85.38

Noticias sobre sentimiento de mercado

By Acuity

58%

42%

302 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

29.78 / 33.645 Soporte y Resistencia

Ionis Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 feb 2026, 23:07 UTC

Ganancias

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb 2026, 23:01 UTC

Ganancias

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb 2026, 22:59 UTC

Ganancias

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 feb 2026, 22:42 UTC

Ganancias

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 feb 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 feb 2026, 23:46 UTC

Charlas de Mercado

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 feb 2026, 23:36 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 feb 2026, 23:30 UTC

Charlas de Mercado

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 feb 2026, 23:20 UTC

Charlas de Mercado

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 feb 2026, 23:20 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

24 feb 2026, 23:16 UTC

Ganancias

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 feb 2026, 23:13 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 feb 2026, 23:12 UTC

Ganancias

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 feb 2026, 23:10 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 feb 2026, 23:10 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 feb 2026, 23:08 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 feb 2026, 23:07 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 feb 2026, 22:52 UTC

Ganancias

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb 2026, 22:46 UTC

Ganancias

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Warner Receives New Bid From Paramount -- 3rd Update

24 feb 2026, 22:29 UTC

Ganancias

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 feb 2026, 22:28 UTC

Ganancias

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 feb 2026, 22:27 UTC

Ganancias

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 feb 2026, 22:27 UTC

Ganancias

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 feb 2026, 22:25 UTC

Ganancias

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 feb 2026, 22:24 UTC

Ganancias

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 feb 2026, 22:23 UTC

Ganancias

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 feb 2026, 22:22 UTC

Ganancias

Woolworths Interim Dividend 45 Australian Cents/Share

24 feb 2026, 22:22 UTC

Ganancias

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 feb 2026, 22:21 UTC

Ganancias

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

14.92% repunte

Estimación a 12 Meses

Media 97.22 USD 14.92%

Máximo 110 USD

Mínimo 87 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

29.78 / 33.645Soporte y Resistencia

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Sentimiento

By Acuity

302 / 351 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.